Fortress Biotech And Cyprium Therapeutics Announce $4.1M Grant From NINDS To Further ThenDevelopment Of AAV-ATP7A Gene Therapy For Menkes Disease
Portfolio Pulse from Benzinga Newsdesk
Fortress Biotech (FBIO) and Cyprium Therapeutics have received a $4.1M grant from the National Institute of Neurological Disorders and Stroke (NINDS) to advance the development of AAV-ATP7A gene therapy for Menkes Disease. This funding will support further research and development efforts for this rare genetic disorder treatment.
March 04, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fortress Biotech has been awarded a $4.1M grant in partnership with Cyprium Therapeutics by NINDS for the development of a gene therapy for Menkes Disease.
The grant from NINDS to Fortress Biotech and Cyprium Therapeutics is a positive development, indicating strong support and validation from a reputable national institute. This financial backing is likely to accelerate the research and development process for the AAV-ATP7A gene therapy, potentially bringing it closer to market. Such advancements are typically viewed positively by investors, as they enhance the company's portfolio and future revenue prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90